Inhibitory activity of meso-dimercaptosuccinic acid against IMP metallo- β -lactamase variants in Pseudomonas aeruginosa
FEMS Microbiology Letters · 2025
DOI: 10.1093/femsle/fnaf052 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEMS Microbiology Letters, 2025. Verfasst von Jacqueline Findlay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, 1700 Fribourg, Switzerland. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, beta-Lactamases, Anti-Bacterial Agents, Succimer. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg.
Abstract (Originalsprache)
The treatment of infections caused by MBL-producing Pseudomonas aeruginosa, including IMP-producers, can be challenging since MBLs confer resistance to most clinically available ß-lactams, leaving few viable options. Thiol-containing compounds, such as meso-dimercaptosuccinic acid (DMSA), have been suggested as inhibitors of MBLs, and particularly have been proposed to exert effective activity against IMP-1 enzymes. In this context, we sought to determine the activity of DMSA, in combination with carbapenems or cephalosporins, against diverse MBL and carbapenemase variants, particularly focussing on IMP variants. In recombinant strains producing either IMP-1, IMP-10, or IMP-13, both with and without a functional OprD, synergy was observed with ceftazidime (CAZ), cefepime (FEP), and meropenem. Negligible changes were observed for other MBLs and no effect was observed in stains producing KPC-2. Testing of the CAZ/DMSA and FEP/DMSA combinations against clinical IMP-producing P. aeruginosa isolates resulted in fractional inhibitory concentration indexes indicating synergy. Enzymatic assays showed a significantly increased inhibitory activity of DMSA against the IMP variants, compared to the other enzymes tested. These findings highlight a possible role of DMSA or DMSA-like compounds to be developed for the treatment of infections caused by IMP-producing P. aeruginosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, 1700 Fribourg, Switzerland.
- Institute of Microbiology, University Hospital Centre and University of Lausanne, 1011 Lausanne, Switzerland.
- Geneva University Hospitals, Division of Intensive Care, Department of Acute Care Medicine, 1205 Geneva, Switzerland.
- Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, 1700 Fribourg, Switzerland.
ORCID-Profile: Jacqueline Findlay, Christophe Le Terrier, Patrice Nordmann
Förderung
- University of Fribourg
Zitieren
APA
Findlay, J., Moreno, H., Greub, G., Le Terrier, C., Bouvier, M., & Nordmann, P. (2025). Inhibitory activity of meso-dimercaptosuccinic acid against IMP metallo- β -lactamase variants in Pseudomonas aeruginosa. FEMS Microbiology Letters. https://doi.org/10.1093/femsle/fnaf052
Vancouver
Findlay J, Moreno H, Greub G, Le Terrier C, Bouvier M, Nordmann P. Inhibitory activity of meso-dimercaptosuccinic acid against IMP metallo- β -lactamase variants in Pseudomonas aeruginosa. FEMS Microbiology Letters. 2025. doi:10.1093/femsle/fnaf052
BibTeX
@article{Findlay2025,
author = {Findlay, Jacqueline and Moreno, Hector and Greub, Gilbert and Le Terrier, Christophe and Bouvier, Maxime and Nordmann, Patrice},
title = {Inhibitory activity of meso-dimercaptosuccinic acid against IMP metallo- β -lactamase variants in Pseudomonas aeruginosa},
journal = {FEMS Microbiology Letters},
year = {2025},
doi = {10.1093/femsle/fnaf052}
}
EUVIMED